KANNAPOLIS, N.C.--(BUSINESS WIRE)--The David H. Murdock Research Institute (DHMRI) at the NC Research Campus and Crown Bioscience, Inc., a leading global drug discovery and development service company headquartered in Santa Clara, CA, announce the opening of the Crown Bioscience US Research Center.
The new center will open later this year and house both Crown’s ongoing cardiovascular and metabolic disease (CVMD) research and a new Translational Oncology Center. The CVMD program leverages research and experimental models to support pharmaceutical partners in their diabetes drug discovery and development. The new oncology center will offer U.S. based pharmaceutical and biotech partners greater access to proprietary Western-patient derived xenograph models to improve the selection and development of promising clinical therapeutic candidates.
By locating the center at the DHMRI, Crown and its partners can take advantage of the advanced immunology technologies available at the Institute. In addition to a variety of research platforms, the DHMRI offers collaborators flow cytometry, immunoassay, clinical chemistry and ELISA analytical services. The Institute will provide Crown’s partners a single facility for both compound screening and sample analysis thereby accelerating their research and reducing the cost to bring therapies to market.
Dr. Jean-Pierre Wery, President of Crown Bioscience, commented: “The opening of a new center at DHMRI marks an important milestone for Crown. In addition to increasing our capacity for running Western patient derived PDX studies and trials, it presents the opportunity to expand and develop our new immunotherapeutic translational technology platforms. The facilities available to us at the DHMRI are excellent, and will greatly benefit our work in translational research across oncology and metabolic disease. We are looking forward to opening the center this year, and building a long-standing relationship with the DHMRI.”
Benjamin Machon, DHMRI Business Development Director, commented: “Crown has been an excellent partner for the DHMRI. We see this as an opportunity to grow both organizations and strengthen collaborations with pharmaceutical and biotechnology companies globally.”
About the DHMRI
DHMRI, which is located on the NC Research Campus in Kannapolis, NC, provides a multidisciplinary approach integrating genomics, analytical sciences, cellular sciences and bioinformatics to accelerate the R&D of companies, institutions and researchers throughout the world as well as the NCRC’s university, corporate and healthcare partners. To learn more, visit http://www.dhmri.org.
About Crown Bioscience Inc.
Founded in 2006, Crown Bioscience is a premier drug discovery and development service company providing cutting-edge translational platforms and cost effective drug discovery solutions for its biotech and pharmaceutical partners in dedicated therapeutic areas: Oncology and Metabolic Disease. Our proprietary HuPrime®, HuKemia®, HuBase™, HuMark™, HuTrial™ and HuSignature™ platforms enable unique lead optimization and translational strategies to deliver superior clinical candidates. Headquartered in Santa Clara California, Crown Bioscience has operations in China (Beijing and Jiangsu Taicang), United Kingdom (Precos, Ltd. In Nottingham) and the USA (NC) with business offices in Boston, Princeton, RTP, Phoenix, Milan and Shanghai. For more information, visit http://www.crownbio.com.